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ABSTRACT 
 
Objective: The objective of this systematic review is to determine whether or not “Does fish oil 
supplementation (omega-3 PUFA) cause mood improvement in adults with depression?”  
 
Study Design:  Review of all English language primary double blind randomized controlled trial 
studies from 1997-2010 
 
Data Sources:  Randomized, controlled, double-blind clinical trials comparing fish oil 
supplementation to placebo were found using OVID, PubMed, Medline and Cochrane databases 
 
Outcomes Measured:  Each of the three trials compared mood improvement in depressed 
patients using depression scales, such as the Hamilton Rating Scale for Depression and the Beck 
Depression Inventory, and subjective ratings, such as aches/pains, energy, fatigue, sleep and 
appetite.  Study participants were evaluated at baseline and subsequently evaluated at 2-3 week 
increments for 8, 12 or 16 weeks.   
 
Results:  Three double-blind randomized controlled trials were included in this review.  The 
study done by Kuan-Pin used 440mg EPA and 220mg DHA and indicated a significant reduction 
in HRSD score for the omega-3 PUFA group in comparison to the placebo group beginning at 
the fourth week of the trial.  The remaining two studies, by Grenyer and Silvers, used 0.6g EPA 
and 2.2 and 2.4g DHA, respectively, and did not find any significant difference in mood 
improvement between participants taking omega-3 PUFA and participants in the placebo group.  
Participants in each of the three studies reported minor adverse effects however none 
encountered any major adverse effects caused by the therapy.   
 
Conclusions:  The results of the Kuan-Pin trial using 440mg EPA and 220mg DHA showed that 
omega-3 PUFA may be effective in improving mood in adults with depression based on the 
Hamilton Rating Scale for Depression.  The Grenyer and Silvers study using 0.6gEPA and 2.2 
and 2.4g DHA, respectively, did not show a significant improvement in mood for adult 
depression patients using the therapy.   
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INTRODUCTION 
 Depression is defined as a depressed mood that is present daily and persists for at least a 
period of two weeks.  Frequent episode characterizations of depression include anhedonia, 
apathy, sadness or irritability.  It is one of the most common mental health problems experienced 
by individuals in the United States marked by a lifetime prevalence of 16.2%.  Onset occurs 
anywhere from childhood to late life; however, the mean age of onset is the late 20s, with the 
incidence rate for adult women twice as great in comparison to men.  The effect of depression on 
an individual not only causes emotional instability, but also physical signs and symptoms.   
 Patients affected by depression often do not seek medical care for the illness, which 
accounts for an extensive number of undiagnosed cases.  While the exact number of annual 
healthcare visits for depression is unknown, data does show that depressed individuals most 
often present to primary care physicians and emergency rooms.  The estimated cost of depression 
for the US economy is $43 billion annually.  These expenses are related to care, absenteeism, 
reduced productivity on the job, premature death and suicide.  The total amount of US healthcare 
expenses for the treatment of depression amounts to $12 billion per year.   
 The exact etiology of depression remains unknown; yet, there are a number of factors that 
are theorized to increase a person’s risk for the disease: genetics, neurotransmitter alterations, 
neuroendocrine dysregulations, negative life events, and stressful environments.  A patient 
presenting with depression admits to depressed mood and anhedonia daily for at least two weeks, 
as well as five or more of the following clinical features: sleep (insomnia or hypersomnia), 
decreased interest, guilt and worthlessness, fatigue, impaired concentration, decreased or 
increased appetite, psychomotor retardation or agitation, suicide, or somatic complaints 
(headache, backache, GI complaints, dizziness, lethargy).  The mainstays of treatment for 
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depression include psychotherapy and pharmacotherapy, with best results stemming from the 
combination of the two.  OTC remedies such as St. John’s Wort are also used as adjuvant 
therapies for depressed patients.  Persistent cases of depressions despite the use of 
pharmacological and behavioral therapies may benefit from surgical interventions such as 
electroconvulsive therapy or vagus nerve stimulation.  The forementioned depression treatment 
options require extended periods of time before effective and are often associated with negative 
side effects.  In lieu of this, fish oil supplementation may provide significant improvement in 
mood for depressed adults over other products and therapies, giving healthcare providers the 
option of introducing omega-3 PUFA supplements into the course treatment of individuals 
affected by major depressive disorder.   
OBJECTIVE 
 The objective of this systematic review is to determine whether or not “Does fish oil 
supplementation (omega-3 PUFA) cause mood improvement in adults with depression?” 
METHODS 
 All three studies selected for this review met the following criteria.  The population 
included adults age 18 and older with a clinical diagnosis of depression.  The intervention used 
in the studies was fish oil (omega-3 PUFA) supplementation in the following three doses: 440mg 
EPA and 220mg DHA (Kuan-Pin et al), 0.6g EPA and 2.2g DHA (Grenyer et al) and 0.6g EPA 
and 2.4g DHA (Silvers et al).  Only those articles that compared the treatment groups receiving 
omega-3 PUFA supplementation compared to a placebo group were considered.  Outcomes were 
based on mood improvement in depressed patients using depression scales and subjective 
ratings, which qualifies as patient oriented evidence that matters (POEM).  Three double-blind, 
randomized, placebo-controlled clinical trials were identified and included in this review.   
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 The key words fish oil, omega-3 fatty acids, and depression were used in combination to 
search literature for English articles, of which all resulting articles were published in peer-
reviewed journals.  A detailed literature search and selection of studies for this review was 
completed by the author using OVID, Medline, PubMed and Cochrane databases.  Inclusion 
studies were those that were randomized, controlled, prospective and based on patients outcomes 
(POEMS) dated after 1996.  Studies excluded from this review were articles that included 
patients less than 18 years of age.  Statistics utilized in the studies include p-values, NNH, chi-
square, t-test, and Intention to Treat (ITT).   
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Table 1: Demographics and characteristics included for analysis of fish oil supplementation in 
the treatment of depression 
Study Type #  
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion  
Criteria 
W/D Interventions 
Grenyer, 
2007 (1) 
Double
-blind 
RCT 
83 18-
70 
Pts with a 
primary 
diagnosis of 
major 
depression 
based on 
DSM-IV 
criteria and 
HDRS score 
>16 
Pts with a serious 
medical condition, 
objection to 
venipuncture, co-
morbid substance 
abuse, psychotic, 
bipolar or eating 
disorder, or OCD 
23 Eight 1g soft 
gelatin 
capsule of 
pacific tuna 
oil (provided 
3g of omega-
3 PUFA) per 
day VS. 
Eight 1g soft 
gel capsules 
of olive oil 
per day for 
16 weeks 
Silvers, 
2005 (2) 
Double
-blind 
RCT 
77 18-
65 
Healthy 
males and 
females 
between the 
ages of 18-65 
with a 
current 
diagnosis of 
depression ad 
current 
medication 
use >2 
months 
Pts with a co-existing 
psychiatric disorder, 
post-menopausal or 
irregular menstruation 
cycle (females), blood 
clotting disorder, use 
of anticoagulants, 
unstable medical 
condition, seafood 
allergies, objections to 
taking fish oil or olive 
oil-based products, or 
objections to 
venipuncture 
18 8g soft gel 
capsule of 
DHA 
enriched tuna 
fish oil per 
day VS. 8g 
soft gel 
capsule of 
olive oil per 
day for 12 
weeks 
Kuan-
Pin, 
2003 (3) 
Double
-blind 
RCT 
32 18-
60 
Healthy pts 
from 18-60yo 
with a major 
depressive 
diagnosis 
based upon 
DSM-IV 
criteria and 
>18 on 
Hamilton 
Rating Scale 
for 
Depression  
Pts with co-morbid 
Axis I or II psychiatric 
disorder, change in 
medications or 
psychotherapy 4 
weeks prior to 
enrollment, 
incompetent or unable 
to understand study 
rules, >20% decreased 
in HRSD score during 
placebo-lead-in phase 
10 Five gelatin 
capsules 
containing 
omega-3 
fatty acids 
BID VS. five 
gelatin 
capsules 
containing 
olive oil 
ethyl esters 
BID for 8 
weeks  
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OUTCOME MEASURED 
 Each of the three studies measured participants’ outcome of mood improvement based on 
depression scales and subjective ratings.  Depression scales included the 21-item Hamilton 
Depression Rating Scale (Kuan-Pin et al, Silvers et al and Grenyer et al) and the Beck 
Depression Inventory (Silvers et al and Grenyer et al).  HDRS is a 21-question survey performed 
by a healthcare professional that assesses a patient’s severity of depression.  Assessment 
questions include the following topics: depressed mood, feelings of guilt, suicide, insomnia, 
work and activities, psychomotor retardation, agitation, psychological agitation, anxiety, somatic 
symptoms, genital symptoms, hypochondriasis, weight loss, insight, diurnal variation, 
depersonalization, paranoid symptoms and obsessive and compulsive symptoms. Scores between 
7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and 
scores over 24 indicate severe depression.  BDI is a 21-item self-report survey that also assesses 
depression severity.  Each answer is scored on a scale from 0-3. Score breakdown is as follows: 
0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; and 29-63: 
severe depression.  As the same with HDRS, higher total scores for BDI indicates more severe 
depressive symptoms. Subjective ratings took into account participants’ degree of aches/pains, 
energy, fatigue, sleep, and appetite. 
 The Global Assessment of Functioning (GAF) was used by Grenyer as a secondary 
means of measuring patient outcomes.  GAF is a numeric scale (0-100) that is used by therapists 
and physicians to subjectively assess adult function in social, occupational and psychological 
aspects of life.   
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RESULTS 
 The three randomized controlled trials presented in this review are double-blind, 
prospective clinical trials that provided continuous data to assess the outcome of mood 
improvement in adults with a clinical diagnosis of depression.  Treatment results were based on 
changes in HRDS scores (Kuan-Pin and Silvers) or BDI scores (Silvers and Grenyer) as shown 
in Table 2.  Analysis of harm for all three studies was done by converting the continuous data to 
dichotomous data and presented as NNH (number needed to harm) analysis (Table 3).   
 The Kuan-Pin study, which originally enrolled 32 participants, completed the eight-week 
trial with a total of 22 participants ranging from 18-60 years old.  At baseline, the omega-3 
PUFA group had a mean HRSD score of 22.5, while the mean score for the placebo group was 
22.1.  The experimental group received a total of 4,400mg EPA and 2,200mg DHA per day.  
Participants were assessed at weeks 0, 2, 4, 6 and 8.  At week 8, participants in the omega-3 
PUFA group had a mean HRSD score of 8.9, while participants in the placebo group had a mean 
score of 15.7.  According to the study, the percent reduction in HRSD scores for the omega-3 
PUFA group was significantly greater than that of the placebo group (p = 0.001).  
 Silvers et al randomly assigned 40 participants to receive fish oil and 37 participants to 
receive placebo.  At completion of the 12-week study, the trial participant composition included 
24 fish oil participants and 21 placebo participants, all of which fell into the age group of 18-65.  
Each participant of the fish oil group received a total of 0.6g EPA and 2.4g DHA per day.  
Assessment of mood took place at baseline, and then at weeks 2, 4, 8 and 12 using the self-
administered HDRS and Beck Depression Inventory (BDI).  Mean baseline HDRS scores for the 
fish oil group and placebo group were 12.4 and 11.5, respectively.  The fish oil group and 
placebo group mean BDI scores at baseline were 23.3 and 21.9, respectively.  At week 12, the 
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placebo group and fish oil group had a mean change in HDRS score of 0.6 (p = 0.6) and 0.3 (p = 
0.8), respectively.  Mean changes in BDI scores were 1.5 (p = 1.5) and 0.3 (p = 1.5) for the 
placebo group and fish oil group, respectively. According to this data, there is no evidence that 
fish oil improved mood for enrolled participants.  
 Grenyer et al randomized 83 participants aged 18-70 to fish oil or placebo at the start of 
the study, with 60 participants completing the 16-week trial (28 placebo and 32 fish oil). Each 
participant of the fish oil group received 2.2g DHA and 0.6g EPA per day.  Mood assessments 
were completed at week 0, 3, 6, 9, 12 and 16 using the HDRS and BDI.  According to Grenyer, 
there was no significant interaction effect between time and group according to both the HDRS 
and BDI with p-values equaling .844 and .424, respectively.  Mean BDI scores for the placebo 
group and fish oil group at baseline were 28 and 25, respectively.  Upon completion of the trial, 
mean BDI scores for placebo and fish oil participants were 17.5 and 12, respectively. The overall 
Global Assessment of Functioning (GAF) scores did improve for both groups over time; baseline 
GAF scores averaged at 51 and improved to an average of 68 at week 16.  Despite this, the 
scores were not found to be significant (p = .399).  In terms of subjective ratings, Grenyer noted 
no differences in aches/pains, energy, fatigue, sleep or appetite between groups over the course 
of the 16 weeks.  
Table 2: Efficacy of fish oil on mood improvement for depressed adults  
Study 
Baseline 
HDRS 
Fish oil 
Group 
Post-tx 
HDRS 
Fish oil 
Group 
Baseline 
HDRS 
Placebo 
Group 
Post-tx 
HDRS 
Placebo 
Group 
Baseline 
BDI 
Fish oil 
Group 
Post-tx 
BDI 
Fish oil 
Group 
Baseline 
BDI 
Placebo 
Group 
Post-tx 
BDI 
Placebo 
Group 
Kuan-
Pin 
22.5 8.9 22.1 15.7 X X X X 
Silvers 11.5 11.8 12.4 13.0 21.9 22.2 23.3 24.8 
Grenyer 23.5 10.7 Unknown Unknown 25 12 28 17.5 
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 All three studies presented data in the form of continuous data.  In order to analyze the 
harm for each trial, the data was converted into dichotomous data and analyzed as NNH.  
Participants that experienced no adverse effects to mild adverse symptoms were considered to 
have insignificant changes, while participants with marked adverse effects were considered 
significant changes.  The CER (control event rate) was determined by the number of patients that 
experienced adverse symptoms as part of the placebo group.  The EER (experimental event rate) 
was based upon the percentage of patients in the fish oil group that experienced significant 
negative effects.  Using this data, RRI (relative risk increase) and ARI (absolute risk increase) 
was calculated.  NNH (number needed to harm) is the number of patients that need to be treated 
with fish oil before a detrimental event occurs.   
Table 3: Analysis of harm based on participants treated with fish oil vs. placebo for depression  
Study # participants CER EER RRI ARI NNH 
Kuan-Pin 32 10%` 17% 70% 7% 14 
Silvers 77 37% 35% 5% -2% 50 
Grenyer 83 0% 78 0 78 1 
 
 The most common side effects noted by Silvers et al were gastrointestinal disturbance 
and/or reflux, which were experienced by both the experimental and control groups.  The only 
adverse effect experienced by participants of the Grenyer trial was a change in stools.  This was 
experienced equally among the fish oil and placebo groups.  Kuan-Pin et al noted that among the 
fish oil participants, one experienced mild excitement and another had mild diarrhea.  One 
participant in the placebo group experienced insomnia for a two-week period during the course 
of study.  Among all three studies presented, none of the participants experienced any major 
adverse effects related to the therapies provided throughout the trial.   
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 Compliance issues were not a major factor for any of the three studies.  Grenyer et al lost 
23% of participants originally enrolled in the study due to violation of the trial protocol.  
Reasons included time/commitment, moving out of area, hospitalizations and time constraints.  
Grenyer noted that analyses of completers versus drop outs found no significant differences in 
measures at any point in time.  According to Silvers et al, 63% of participants in the fish oil 
group and 63% of participants in the placebo group admitted to non-compliance with doses.  
Reasons included unable to take capsules as requested, capsules too large to swallow, GI 
disturbances, capsules showed no improvements, or stopped capsules because improvements 
were experienced.  In lieu of this, there was no evidence that non-compliance was related to the 
assigned therapy (p = 0.976).  Kuan-Pin et al lost six participants during the eight-week course of 
the study (2 fish oil and 4 placebo).  Reasons were due to lost in follow-up or non-compliance.   
DISCUSSION 
 Omega-3 fatty acids are a family of unsaturated fatty acids with a common carbon-carbon 
double bond located at the n-3 position.  Two of the most common types are eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), both of which are polyunsaturated fatty acids.  
Since the body is unable to synthesize omega-3 fatty acids on its own, individuals must obtain 
sources from food or supplementation.  It is widely known that omega-3 fatty acids are an 
essential component for normal growth and development, but recent studies have since increased 
our knowledge surrounding the associated health benefits.  Most notably, omega-3 fatty acids are 
used to treat patients with hypertriglyceridemia, coronary artery disease, and hypertension.  The 
American Heart Association recommends that patients with coronary artery disease consume 1g 
of fish oil per day, preferably by eating fish. Lovanza, a new drug on the market indicated for 
patients with severe hypertriglyceridemia, is composed of a combination of ethyl esters of 
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omega-3 fatty acids, principally EPA and DHA.  For individuals that do not meet criteria for 
prescription omega-3 fatty acids, supplements are widely available OTC at pharmacies 
throughout the US.  Other conditions known to benefit from fish oil ingestion include cancer 
(particularly breast, colon and prostate cancer), Alzheimer’s and Parkinson’s disease.  While 
negative symptoms associated with fish oil supplementation is rare, one of the major adverse 
effects is prolonged bleeding times; doses of omega-3 fatty acids that exceed 3 grams per day 
may increase a patient’s risk of bleeding and could put a person at risk for hemorrhagic stroke.  
Omega-3 fatty acids also have been shown to increase levels of LDLs, which should be used 
cautiously in patients with a history of hyperlipidemia.   
 The three studies presented in this review were all faced with certain limitations.  27% of 
participants in the Grenyer study, 23% of participants in the Silvers study, and 31% of 
participants in the Kuan-Pin study withdrew from the trial throughout the course of study.  The 
potential outcomes associated with those participants were not analyzed as part of each study, 
but could have significantly impacted results if experimental participant HRDS or BDI scores 
were statistically significant in comparison to placebo.  Silvers et al measured patient outcomes 
based on self-administered ratings only.  In comparison, Kuan-Pin et al and Grenyer et al used 
self-administered ratings as well as healthcare professional survey scores to measures the 
outcomes of mood improvement for enrolled participants.  Allowing individuals to assess their 
own mood improvement leaves room for dishonesty, resulting in unreliable data.  In all three 
studies, participants often correctly guessed to which group they were randomized based upon 
the fishy aftertaste of the fish oil capsules.  Future studies would benefit from concealing the fish 
oil taste by alternate means in order to devise a completely blinded trial.     
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CONCLUSIONS 
 The three studies reviewed for this paper provided each of their respective experimental 
fish oil groups with a certain dosage of EPA and DHA, both of which belong to the family of 
omega-3 PUFA.  Two of the three studies determined that daily fish oil intake had no impact on 
mood improvement in adult patients with a clinical diagnosis of depression.  The remaining 
study noted that while fish oil participants did in fact see an improvement in mood over the 
course of the trial, there is need for further studies in order to truly determine the effectiveness of 
omega-3 PUFA supplementation.  Taking all results into consideration, it is decided that adult 
depression patients cannot use fish oil supplements as a means to improve mood.  Future studies 
may wish to experiment with other types of omega-3 PUFA, instead of relying solely on EPA 
and DHA.   
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